BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 11172947)

  • 1. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
    Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
    Kornek GV; Schratter-Sehn A; Marczell A; Depisch D; Karner J; Krauss G; Haider K; Kwasny W; Locker G; Scheithauer W
    Br J Cancer; 2000 Jan; 82(1):98-103. PubMed ID: 10638974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
    Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
    Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
    Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
    Yavuz AA; Aydin F; Yavuz MN; Ilis E; Ozdemir F
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):974-81. PubMed ID: 11704320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
    Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
    Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
    Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
    Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
    Haddock MG; Swaminathan R; Foster NR; Hauge MD; Martenson JA; Camoriano JK; Stella PJ; Tenglin RC; Schaefer PL; Moore DF; Alberts SR
    J Clin Oncol; 2007 Jun; 25(18):2567-72. PubMed ID: 17577035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
    Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
    Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
    Aparicio J; García-Mora C; Martín M; Petriz ML; Feliu J; Sánchez-Santos ME; Ayuso JR; Fuster D; Conill C; Maurel J
    PLoS One; 2014; 9(1):e82209. PubMed ID: 24416138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
    Iannitti D; Dipetrillo T; Akerman P; Barnett JM; Maia-Acuna C; Cruff D; Miner T; Martel D; Cioffi W; Remis M; Kennedy T; Safran H
    Am J Clin Oncol; 2005 Dec; 28(6):570-5. PubMed ID: 16317266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
    Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
    JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
    Shiah HS; Cheng AL; Hsu C; Hsu CH; Liu TW; Chang JY; Jan CM; Chao Y; Yu WL; Chuang TR; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 Mar; 21(3):531-6. PubMed ID: 16638094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
    Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.